Literature DB >> 11208187

Removal of bowel aerobic gram-negative bacteria is more effective than immunosuppression with cyclophosphamide and steroids to decrease natural alpha-galactosyl IgG antibodies.

R Mañez1, F J Blanco, I Díaz, A Centeno, E Lopez-Pelaez, M Hermida, H F Davies, A Katopodis.   

Abstract

Natural alpha-Galactosyl (Gal) antibodies play an important role in the rejection of pig xenografts by humans and Old World monkeys. In this study we investigate the efficacy of two different strategies to reduce the serum level of natural anti-Gal antibodies. On the one hand, removal of aerobic gram-negative bacteria from the intestinal flora, because anti-Gal antibodies appear to be produced as a result of the continuous sensitization by these microorganisms. On the other hand, we studied the effect on these antibodies of an immunosuppressive regimen of cyclophosphamide and steroids. Ten baboons were treated for three months with norfloxacin (Nor Group; n=6) or cyclophosphamide and steroids (CyP Group; n=4). A further four baboons did not receive any treatment (Control Group). Aerobic gram-negative bacteria became negative in stools of the Nor Group after two weeks of treatment, and remained undetectable until week 7. Thereafter, a gradual increase on the fecal concentration of aerobic gram-negative bacteria was observed despite the norfloxacin treatment. The mean anti-Gal IgG in the Nor Group gradually declined from week 4 to 9 to a mean of 62.7 +/- 18% of the baseline level, and during this period were significantly lower than in the CyP (P<0.02) and the Control (P<0.05) groups. No differences were observed between the three groups during the 16 weeks of follow-up in serum levels of anti-Gal IgM, hemolytic anti-pig antibodies, total IgG, IgM and IgA. In conclusion, removal of normal aerobic gram-negative bacteria from the intestinal flora is more effective than immunosuppression with CyP and steroids in reducing the level of natural anti-Gal antibodies, although there is no discernible effect on IgM antibodies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11208187     DOI: 10.1034/j.1399-3089.2001.00082.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  12 in total

1.  Induction of cytolytic anti-Gal antibodies in alpha-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria.

Authors:  Karla J Posekany; H Keith Pittman; John F Bradfield; Carl E Haisch; Kathryn M Verbanac
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

2.  A dataset for the analysis of antibody response to glycan alpha-Gal in individuals with immune-mediated disorders.

Authors:  José de la Fuente; José Miguel Urra; Marinela Contreras; Iván Pacheco; Elisa Ferreras-Colino; Ernesto Doncel-Pérez; Isabel G Fernández de Mera; Margarita Villar; Carmen M Cabrera; Cesar Gómez Hernando; Eduardo Vargas Baquero; Javier Blanco García; Javier Rodríguez Gómez; Alberto Velayos Galán; Francisco Feo Brito; Elisa Gómez Torrijos; Alejandro Cabezas-Cruz; Christian Gortázar
Journal:  F1000Res       Date:  2020-11-24

3.  Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti).

Authors:  Milan Thorel; Lourdes Mateos-Hernandez; Baptiste Mulot; Mouna Naila Azzouni; Adnan Hodžić; Hugues Gaillot; Yannick Ruel; Guillaume Desoubeaux; Jean-Baptiste Delaye; Dasiel Obregon; Alejandra Wu-Chuang; José de la Fuente; Luis G Bermúdez-Humarán; Veronica Risco-Castillo; Antoine Leclerc; Alejandro Cabezas-Cruz
Journal:  Front Immunol       Date:  2022-05-13       Impact factor: 8.786

4.  Boosted rat natural xenoantibodies cross-react with Enterococcus faecalis by targeting melibiose and L-rhamnose.

Authors:  Magdiel Perez-Cruz; Cristina Costa; Rafael Mañez
Journal:  J Innate Immun       Date:  2013-11-15       Impact factor: 7.349

5.  Divergence of the response induced by xenogenic immunization in the sepsis survival of rats.

Authors:  Magdiel Perez-Cruz; Cristina Costa; Rafael Manez
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

6.  Immunity to α-Gal: The Opportunity for Malaria and Tuberculosis Control.

Authors:  Alejandro Cabezas-Cruz; José de la Fuente
Journal:  Front Immunol       Date:  2017-12-04       Impact factor: 7.561

Review 7.  Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.

Authors:  Uri Galili
Journal:  Vaccine       Date:  2020-08-19       Impact factor: 3.641

Review 8.  In Situ "Humanization" of Porcine Bioprostheses: Demonstration of Tendon Bioprostheses Conversion into Human ACL and Possible Implications for Heart Valve Bioprostheses.

Authors:  Uri Galili; Kevin R Stone
Journal:  Bioengineering (Basel)       Date:  2021-01-12

9.  Gut microbiota elicits a protective immune response against malaria transmission.

Authors:  Bahtiyar Yilmaz; Silvia Portugal; Tuan M Tran; Raffaella Gozzelino; Susana Ramos; Joana Gomes; Ana Regalado; Peter J Cowan; Anthony J F d'Apice; Anita S Chong; Ogobara K Doumbo; Boubacar Traore; Peter D Crompton; Henrique Silveira; Miguel P Soares
Journal:  Cell       Date:  2014-12-04       Impact factor: 41.582

Review 10.  Host Synthesized Carbohydrate Antigens on Viral Glycoproteins as "Achilles' Heel" of Viruses Contributing to Anti-Viral Immune Protection.

Authors:  Uri Galili
Journal:  Int J Mol Sci       Date:  2020-09-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.